Reviewing CapsoVision (CV) & Its Competitors

CapsoVision (NASDAQ:CV – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare CapsoVision to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.

Earnings & Valuation

This table compares CapsoVision and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CapsoVision $13.55 million -$25.32 million -13.77
CapsoVision Competitors $1.89 billion $135.83 million 5.73

CapsoVision’s rivals have higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares CapsoVision and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CapsoVision -210.09% -188.10% -139.99%
CapsoVision Competitors -270.28% -155.47% -22.38%

Risk and Volatility

CapsoVision has a beta of -2.34, indicating that its stock price is 334% less volatile than the S&P 500. Comparatively, CapsoVision’s rivals have a beta of 2.58, indicating that their average stock price is 158% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for CapsoVision and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision 1 1 2 0 2.25
CapsoVision Competitors 4311 10599 18393 838 2.46

CapsoVision presently has a consensus price target of $9.50, indicating a potential upside of 46.83%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.19%. Given CapsoVision’s higher probable upside, analysts clearly believe CapsoVision is more favorable than its rivals.

Summary

CapsoVision rivals beat CapsoVision on 11 of the 13 factors compared.

About CapsoVision

(Get Free Report)

CapsoVision develops medical technology for capsule endoscopy, a method of examining the digestive tract using a swallowable camera. Its products are designed to help clinicians visualize the small intestine as part of diagnostic evaluation. The company’s CapsoCam Plus system uses a swallowable capsule with multiple cameras to capture panoramic images as it moves through the small intestine. Images are stored in the capsule and later retrieved for review using the company’s supporting hardware and software.

Receive News & Ratings for CapsoVision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CapsoVision and related companies with MarketBeat.com's FREE daily email newsletter.